147 related articles for article (PubMed ID: 16265616)
1. Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future.
Shire NJ; Sherman KE
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S63-8. PubMed ID: 16265616
[TBL] [Abstract][Full Text] [Related]
2. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
Bräu N
Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
[TBL] [Abstract][Full Text] [Related]
4. Management of hepatitis C virus coinfection in HIV-infected persons.
O'Leary JG; Chung RT
AIDS Read; 2006 Jun; 16(6):313-6, 318-20. PubMed ID: 16795921
[TBL] [Abstract][Full Text] [Related]
5. HIV and hepatitis C virus coinfection: bad bedfellows.
Schooley RT
Top HIV Med; 2005; 13(4):112-6. PubMed ID: 16304454
[TBL] [Abstract][Full Text] [Related]
6. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
Bräu N
J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419
[TBL] [Abstract][Full Text] [Related]
7. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
8. HIV/HCV coinfection in clinical practice.
Dieterich DT; Kontorinis N; Agarwal K
J Int Assoc Physicians AIDS Care (Chic); 2004 Oct; 3 Suppl 1():S4-14; quiz S16-7. PubMed ID: 15566014
[TBL] [Abstract][Full Text] [Related]
9. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
Nattermann J; Vogel M; Berg T; Danta M; Axel B; Mayr C; Bruno R; Tural C; Klausen G; Clotet B; Lutz T; Grünhage F; Rausch M; Nischalke HD; Schewe K; Bienek B; Haerter G; Sauerbruch T; Rockstroh JK; Spengler U;
Hepatology; 2007 Oct; 46(4):1016-25. PubMed ID: 17668881
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
[TBL] [Abstract][Full Text] [Related]
11. Management of hepatitis C in HIV infected and other immunocompromised individuals.
Seth AK
Trop Gastroenterol; 2006; 27(3):111-7. PubMed ID: 17310553
[TBL] [Abstract][Full Text] [Related]
12. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
Martel-Laferrière V; Brinkley S; Bichoupan K; Posner S; Stivala A; Perumalswami P; Schiano T; Sulkowski M; Dieterich D; Branch A
HIV Med; 2014 Feb; 15(2):108-15. PubMed ID: 24025147
[TBL] [Abstract][Full Text] [Related]
13. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.
Deming P; McNicholl IR
Pharmacotherapy; 2011 Apr; 31(4):357-68. PubMed ID: 21449625
[TBL] [Abstract][Full Text] [Related]
14. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
Fuster D; Planas R; Gonzalez J; Force L; Cervantes M; Vilaró J; Roget M; García I; Pedrol E; Tor J; Ballesteros AL; Salas A; Sirera G; Videla S; Clotet B; Tural C
Antivir Ther; 2006; 11(4):473-82. PubMed ID: 16856621
[TBL] [Abstract][Full Text] [Related]
15. Viral hepatitis and HIV: update and management.
Núñez M; Mendes-Correa MC
Antivir Ther; 2013; 18(3 Pt B):451-8. PubMed ID: 23792670
[TBL] [Abstract][Full Text] [Related]
16. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hepatitis C in HIV/hepatitis C co-infected patients: what is the evidence?
Cacoub P
Int J STD AIDS; 2005 Jan; 16(1):1-4. PubMed ID: 15705263
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
[No Abstract] [Full Text] [Related]
19. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
Pivert A; Payan C; Morand P; Fafi-Kremer S; Deshayes J; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F
J Clin Microbiol; 2006 Feb; 44(2):417-22. PubMed ID: 16455894
[TBL] [Abstract][Full Text] [Related]
20. New paradigms in the management of hepatitis C virus co-infections.
Sherman KE
Nat Clin Pract Gastroenterol Hepatol; 2007 Jan; 4 Suppl 1():S10-6. PubMed ID: 17235280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
